Literature DB >> 15111683

Ropinirole for restless legs syndrome: a placebo-controlled crossover trial.

C H Adler1, R A Hauser, K Sethi, J N Caviness, L Marlor, W M Anderson, J G Hentz.   

Abstract

The authors performed a double-blind, placebo-controlled, crossover study of ropinirole (0.5 to 6.0 mg/day) for restless legs syndrome (RLS). The RLS Rating Scale score improved (p < 0.001) from a mean (SD) of 25 (7) during placebo treatment to 13 (12) during ropinirole treatment. Eight of the 22 patients had complete resolution of symptoms on ropinirole. Adverse events included nausea and dizziness. Ropinirole was effective and well tolerated for treating the symptoms of RLS.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15111683     DOI： 10.1212/01.wnl.0000120672.94060.f1

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  20 in total

Review 1.  Restless legs syndrome: pathophysiology, clinical presentation and management.

Authors:  Claudia Trenkwalder; Walter Paulus
Journal:  Nat Rev Neurol       Date:  2010-06       Impact factor: 42.937

2.  Clinical studies with ropinirole in Parkinson's disease and RLS.

Authors:  Wolfgang H Jost; Dieter Angersbach; Olivier Rascol
Journal:  J Neurol       Date:  2006-08       Impact factor: 4.849

Review 3.  Management of restless legs syndrome in patients on dialysis.

Authors:  Miklos Z Molnar; Marta Novak; Istvan Mucsi
Journal:  Drugs       Date:  2006       Impact factor: 9.546

4.  Recent advances in the diagnosis, genetics and treatment of restless legs syndrome.

Authors:  Claudia Trenkwalder; Birgit Högl; Juliane Winkelmann
Journal:  J Neurol       Date:  2009-04-27       Impact factor: 4.849

Review 5.  The treatment of restless legs syndrome and periodic limb movement disorder in adults--an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine Clinical Practice Guideline.

Authors:  R Nisha Aurora; David A Kristo; Sabin R Bista; James A Rowley; Rochelle S Zak; Kenneth R Casey; Carin I Lamm; Sharon L Tracy; Richard S Rosenberg
Journal:  Sleep       Date:  2012-08-01       Impact factor: 5.849

6.  A randomized, double-blind, placebo-controlled, crossover study of XP13512/GSK1838262 in the treatment of patients with primary restless legs syndrome.

Authors:  Clete A Kushida; Arthur S Walters; Philip Becker; Stephen G Thein; A Thomas Perkins; Thomas Roth; Daniel Canafax; Ronald W Barrett
Journal:  Sleep       Date:  2009-02       Impact factor: 5.849

7.  Ropinirole in restless legs syndrome and periodic limb movement disorder.

Authors:  Daniel Erichsen; Raffaelle Ferri; David Gozal
Journal:  Ther Clin Risk Manag       Date:  2010-04-15       Impact factor: 2.423

Review 8.  Treatment of restless legs syndrome.

Authors:  Cynthia L Comella
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 9.  Effect of nonergot dopamine agonists on symptoms of restless legs syndrome.

Authors:  William L Baker; C Michael White; Craig I Coleman
Journal:  Ann Fam Med       Date:  2008 May-Jun       Impact factor: 5.166

Review 10.  Restless legs syndrome: pathophysiology, diagnosis and treatment.

Authors:  Pankaj Satija; William G Ondo
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.